Introduction {#s1}
============

Brainstem glioma (BSG) encompasses a heterogeneous group of tumors, which are classified according to epidemiological, imaging \[magnetic resonance imaging (MRI)\], and pathological characteristics. Epidemiologically, BSG accounts for 4.3% of all gliomas as recorded in the most recent Central Brain Tumor Registry of the United States (CBTRUS) report ([@B1]). Notably, BSG constitutes \~15% of pediatric brain tumors and \<2% of adult gliomas ([@B1], [@B2]). Based on MRI characteristics and surgical experience, Choux et al. ([@B3]) classified BSG into types of diffuse, intrinsic focal, extrinsic focal, and cervicomedullary, and this remains to be most recent and widely accepted categorization system of BSG. Diffuse brainstem pontine glioma (DIPG) is associated with dismal prognosis in both pediatric and adult patients, being highly infiltrative and less amenable to surgery ([@B4], [@B5]). Pathologically, pediatric and adult patients with high-grade BSG (HGBSG), including World Health Organization (WHO) grades III and IV BSG, have worse clinical outcomes ([@B6], [@B7]). Over the last two decades, we have gained deep understanding on pediatric DIPG and HGBSG in terms of biological characteristics, prognostic factors, and treatment strategies ([@B8]--[@B11]). However, little is known about low-grade BSG (LGBSG) especially its presentation in adult patients. Only few single-center retrospective studies with small population concerning pediatric LGBSG were available. And no study focusing on adult LGBSG has been published to date. Regarding its treatment modalities, surgical resection has improved with advancing imaging and neurosurgery techniques ([@B12]--[@B14]). At the same time, efforts were devoted to investigate the adjuvant therapy including radiotherapy (RT) and chemotherapy (CT) for LGBSG patients ([@B15]--[@B19]). However, there is no consensus on the benefits of surgical resection and adjuvant therapy for LGBSG.

This population-based real-world study was conducted to address this challenge. A search was performed on the SEER (Surveillance Epidemiology and End Results) database, which identified 165 pediatric and 140 adult patients with histologically confirmed LGBSG from 2004 to 2015. The major purpose of this study was to determine the prognostic factors influencing cancer-specific survival (CSS) and overall survival (OS), which could help to optimize the management of patients with LGBSG.

Methods {#s2}
=======

Study Population
----------------

The SEER database, which is maintained by the National Cancer Institute, was searched to identify data deposited between 2004 and 2015. The SEER database provides prospectively collected data on patients with deidentified information. For this reason, no approval was required from the institutional review board for this study. All patients with first and primary brainstem tumor were included. Patients with WHO grade III or IV or unknown WHO grade tumors were excluded. Patients without histologically confirmed glioma and other crucial variates (metastasis, extension, tumor size, reason for death, and surgery status) were also excluded ([Figure 1](#F1){ref-type="fig"}).

![Flowchart of low-grade brainstem glioma patient selection.](fonc-10-00391-g0001){#F1}

Covariates Included
-------------------

The following patient data were obtained for the analysis: age at diagnosis (patients aged \<22 years were assigned to the pediatric group, and those aged ≥22 years were assigned to adult group), sex, race (white, black, American Indian/Alaska Native, Asian/Pacific Islander), marital status (married, unmarried), WHO grade (I, II), surgery \[unknown surgery status, local excision/biopsy, subtotal resection, gross total resection (GTR)\], tumor size (size ≤ 3.6 cm, size \>3.6 cm, the best cutoff value was defined according to X-tile software), metastasis (yes, no), RT and CT (both, none/unknown, RT, CT), and extension pattern (brainstem, cerebellum, ventricular, and other categories). We divided the histological type into diffuse astrocytic and oligodendroglial tumors (DAOTs), other astrocyte tumors (OATs), and ependymal tumors (ETs) according to the 2016 WHO classification of tumors of the central nervous system ([Table 1](#T1){ref-type="table"}).

###### 

Patient demographics, tumor characteristics, and treatment options of 305 low-grade brainstem glioma patients.

  **Characteristic**             **ALL *n* (%)**   **Pediatric *n* (%)**   **Adult *n* (%)**   ***P***
  ------------------------------ ----------------- ----------------------- ------------------- -----------------------------------------
  Population size                305 (100)         165 (54.1)              140 (45.9)          
  Age, median (range), y                           8.31 (\<22)             46.01 (22--85)      
  Era of diagnosis                                                                             0.353
    2004--2009                   134 (43.9)        77 (25.2)               57 (18.7)           
    2010--2015                   171 (56.1)        88 (28.9)               83 (27.2)           
  Sex                                                                                          0.500
    Female                       132 (42.3)        68 (22.3)               64 (20.0)           
    Male                         173 (56.7)        97 (31.8)               76 (24.9)           
  Race                                                                                         0.565
    Asian/Pacific Islander       17 (5.6)          9 (3.0)                 8 (2.6)             
    Black                        27 (8.9)          12 (3.9)                15 (5.0)            
    White                        261 (85.5)        144 (47.2)              117 (38.3)          
  Marital status                                                                               
    Unmarried                    224 (73.4)        164 (53.8)              60 (19.6)           \<0.001[^†^](#TN1){ref-type="table-fn"}
    Married                      81 (26.6)         1 (0.3)                 80 (26.3)           
  WHO grade                                                                                    
    I                            137 (44.9)        98 (32.1)               39 (12.8)           \<0.001[^†^](#TN2){ref-type="table-fn"}
    II                           168 (55.1)        67 (22.0)               101 (33.1)          
  Surgery                                                                                      0.988
    Local excision/biopsy        60 (19.7)         32 (10.5)               28 (9.2)            
    STR                          65 (21.3)         35 (11.5)               30 (9.8)            
    GTR                          180 (59.0)        98 (32.1)               82 (26.9)           
  Size                                                                                         
    ≤ 3.6 cm                     158 (51.8)        66 (21.6)               92 (30.2)           \<0.001[^†^](#TN1){ref-type="table-fn"}
    \>3.6 cm                     147 (48.2)        99 (32.5)               48 (15.7)           
  Metastasis                                                                                   
    Yes                          8 (2.6)           4 (1.3)                 4 (1.3)             1.000
    No                           297 (97.4)        161 (52.8)              136 (46.6)          
  Adjuvant therapy                                                                             
    Both                         18 (5.9)          14 (4.6)                4 (1.3)             \<0.001[^†^](#TN1){ref-type="table-fn"}
    Radiotherapy                 100 (32.8)        42 (13.7)               58 (19.1)           
    Chemotherapy                 25 (8.2)          24 (7.9)                1 (0.3)             
    None/unknown                 162 (53.1)        85 (27.9)               77 (25.2)           
  Extension                                                                                    
    Brainstem                    120 (39.4)        75 (24.6)               45 (14.8)           \<0.001[^†^](#TN1){ref-type="table-fn"}
    Cerebellum                   25 (8.2)          15 (4.9)                10 (3.3)            
    Ventricular                  105 (34.4)        43 (14.1)               62 (20.3)           
    Other                        55 (18.0)         32 (10.5)               23 (7.5)            
  Cancer-specific death status                                                                 
    Alive                        276 (90.5)        155 (50.8)              121 (39.7)          0.042[^†^](#TN1){ref-type="table-fn"}
    Dead                         29 (9.5)          10 (3.3)                19 (6.2)            
  Vital status                                                                                 
    Alive                        265 (86.8)        152 (49.8)              113 (37.0)          0.006[^†^](#TN1){ref-type="table-fn"}
    Dead                         40 (13.2)         13 (4.3)                27 (8.9)            
  Histology                                                                                    
    DAOT                         31 (10.2)         19 (6.2)                12 (4.0)            \<0.001[^†^](#TN1){ref-type="table-fn"}
    ET                           138 (45.2)        45 (14.8)               93 (30.4)           
    OAT                          136 (44.6)        101 (33.1)              35 (11.5)           

*P \< 0.05, statistically significant*.

Statistical Analyses
--------------------

To analyze all different prognostic variables associated with the CSS and OS, both univariate and multivariate cox proportional hazard models were applied to calculate hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs). *P* \< 0.05 was considered statistically significant. And Kaplan--Meier curves and decision tree were plotted to compare the CSS of patients with LGBSG patients by all different prognostic factors. The study population was randomly divided into training group (*n* = 152) and test group (*n* = 153). All different variables were further identified by L1-penalized (Lasso) regression model. The risk scores were then calculated according to the formula, risk score = β1X1+ β2X2 + ... + βnXn (β, regression coefficient; X, prognostic factors). Then a nomogram was developed using the package of RMS in R version 3.5.1 (<http://www.r-project.org/>). A calibration curve was used for internal validation, which described the average predictive value against actual observation and evaluated the performance of nomogram visually. Harrell\'s concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curve were used to evaluate the discrimination of nomogram to assess the consistency between the actual and predicted CSS rate. The clinical use of nomogram was estimated by decision curve analysis (DCA), which is a novel method that estimates predictive models from the perspective of clinical consequences.

Results {#s3}
=======

Patient Population and Baseline Characteristics
-----------------------------------------------

A total of 305 LGBSG patients were analyzed. Among them, 165 were pediatric with a mean age of 8.31 years (\<22 years), and 140 were adult with a mean age of 46.01 years (22--85 years). The data showed that LGBSG had a slight male preponderance (56.7%), but it was not statistically significant (*P* = 0.500). At the time of data collection, the CSS rates for pediatric and adults patients were 93.9 and 86.4%, respectively (*P* = 0.042). Majority of patients were white (*n* = 261, 85.5%), whereas 27 (8.9%) were black, and 17 (5.6%) were Asian/Pacific Islander. The majority of patients were diagnosed during 2010--2015 compared to 2004--2009 (*n* = 171, 56.7% vs. *n* = 134, 43.9%). At the time of data collection, 265 patients (86.8%) were alive, whereas 40 cases (13.2%) had died. Of the 40 deaths, 29 died of cancer-specific events.

Metastasis occurred in eight patients (2.6%), including four pediatric and four adult patients, indicating no difference (*P* = 1.000). In contrast, there were significant differences between pediatric and adult patients in tumor size; the proportion of patients with tumor size \>3.6 cm in the adult groups was significantly lower than that in pediatric patients (34.3 vs. 60.0%, *P* \< 0.001). In terms of tumor extension pattern, it showed significant difference between the two groups (*P* \< 0.001); the proportion of patients with tumor extended to ventricular system in adults was significantly higher than that in pediatric patients (44.3 vs. 26.1%, *P* \< 0.001). Concerning treatment options, the extent of surgery was not significantly different between the two groups (*P* = 0.988). But for adjuvant therapy, notable differences were observed between the two groups; more adult patients received RT (41.4 vs. 25.5%), and fewer adult patients received CT (0.1 vs. 14.5%) (*P* \< 0.001) ([Table 1](#T1){ref-type="table"}).

Prognostic Factors of CSS and OS
--------------------------------

The univariate analysis showed that the pediatric group (HR, 0.39; 95% CI, 0.18--0.84; *P* = 0.016), GTR (HR, 0.28; 95% CI, 0.11--0.69; *P* = 0.005), and extension to ventricular system (HR, 0.36; 95% CI, 0.13--0.99; *P* = 0.049) were associated with increased CSS rate (*P* \< 0.05). In contrast, WHO grade II (HR, 2.69 (1.15--6.30 *P* \< 0.001), DAOT (HR, 5.65; 95% CI, 2.45--13.08; *P* \< 0.001), and RT (HR, 2.46; 95% CI, 0.46--9.71; *P* = 0.028) were significantly associated with decreased CSS rate (*P* \< 0.05). In multivariate analysis, pediatric group (HR, 0.28; 95% CI, 0.10--0.76; *P* = 0.012) and ventricular system involvement (HR, 0.40; 95% CI, 0.14--1.20; *P* = 0.010) were independently associated with improved CSS rate. On the contrary, metastasis (HR, 5.20; 95% CI, 1.03--26.38; *P* = 0.046) and DAOT (HR, 5.14; 95% CI, 1.72--15.39; *P* = 0.003) were independently associated with decreased CSS rate. Analysis of surgical procedures showed that GTR (HR, 0.40; 95% CI, 0.15--1.12; *P* = 0.081) was not significantly associated with better CSS after adjusting for confounding effects of each variable when compared with biopsy group. World Health Organization grade II (HR, 2.57; 95% CI, 0.30--21.75; *P* = 0.386) also lost its significance in multivariate analysis ([Table 2](#T2){ref-type="table"}). The predictive factors of OS were similar, which were only slightly different from those of CSS in HR, 95% CI, and *P*-value ([Table S1](#SM1){ref-type="supplementary-material"}).

###### 

Univariate and multivariate Cox proportional hazard regression analyses to determine prognostic factors of cancer-specific survival for patients with low-grade brainstem glioma.

                             **5-y CSS rate (%)**   **10-y CSS rate (%)**   **Univariate analysis**   **Multivariate analysis**                                      
  -------------------------- ---------------------- ----------------------- ------------------------- ----------------------------------------- -------------------- ---------------------------------------
  Age                                                                                                                                                                
    ≥22 Adult                84.9                   74.7                    1 \[Reference\]                                                     1 \[Reference\]      
    \<22 Pediatric           93.2                   86.6                    0.39 (0.18--0.84)         0.016[^†^](#TN2){ref-type="table-fn"}     0.28 (0.10--0.76)    0.012[^†^](#TN2){ref-type="table-fn"}
  Sex                                                                                                                                                                
    Female                   88.1                   83.5                    1 \[Reference\]                                                     1 \[Reference\]      
    Male                     90.7                   90.7                    0.72 (0.35--1.49)         0.375                                     0.96 (0.42--2.17)    0.918
  Race                                                                                                                                                               
    White                    90.0                   7.6                     1 \[Reference\]                                                     1 \[Reference\]      
    Black                    83.5                   83.5                    1.62 (0.56--4.66)         0.374                                     1.42 (0.46--4.43)    0.545
    Asian/Pacific Islander   90.0                   /                       0.73 (0.10--5.37)         0.753                                     1.41 (0.18--11.22)   0.744
  Marital status                                                                                                                                                     
    Unmarried                88.1                   93.6                    1 \[Reference\]                                                     1 \[Reference\]      
    Married                  85.0                   86.2                    1.02 (0.45--2.31)         0.956                                     0.54 (0.20--1.46)    0.226
  Grade                                                                                                                                                              
    I                        93.6                   93.6                    1 \[Reference\]                                                     1 \[Reference\]      
    II                       86.2                   82.8                    2.69 (1.15--6.30)         \<0.001[^†^](#TN2){ref-type="table-fn"}   2.57 (0.30--21.75)   0.386
  Surgery                                                                                                                                                            
    Local excision/biopsy    81.3                   81.3                    1 \[Reference\]                                                     1 \[Reference\]      
    STR                      79.1                   /                       1.22 (0.50--2.97)         0.659                                     1.64 (0.61--4.40)    0.570
    GTR                      95.5                   93.1                    0.28 (0.11--0.69)         0.005[^†^](#TN2){ref-type="table-fn"}     0.40 (0.15--1.12)    0.081
  Size                                                                                                                                                               
    ≤ 3.6 cm                 88.4                   86.2                    1 \[Reference\]                                                     1 \[Reference\]      
    \>3.6 cm                 90.6                   88.9                    0.82 (0.39--1.70)         0.591                                     1.26 (0.49--3.25)    0.634
  Metastasis                                                                                                                                                         
    No                       90.0                   87.8                    1 \[Reference\]                                                     1 \[Reference\]      
    Yes                      68.6                   /                       2.75 (0.65--11.57)        0.168                                     5.20 (1.03--26.38)   0.046[^†^](#TN2){ref-type="table-fn"}
  Adjuvant therapy                                                                                                                                                   
    None/unknown             93.9                   92.0                    1 \[Reference\]                                                     1 \[Reference\]      
    Radiotherapy             81.6                   81.6                    2.46 (0.46--9.71)         0.028[^†^](#TN2){ref-type="table-fn"}     1.48 (0.57--3.82)    0.421
    Chemotherapy             94.4                   78.7                    1.37 (0.30--6.27)         0.683                                     0.81 (0.14--4.50)    0.806
    Both                     86.2                   /                       2.12 (0.46--9.71)         0.333                                     0.93 (0.16--5.36)    0.938
  Extension                                                                                                                                                          
    Brainstem                85.0                   83.0                    1 \[Reference\]                                                     1 \[Reference\]      
    Cerebellum               92.0                   92.0                    0.58 (0.13--2.51)         0.462                                     0.64 (0.13--3.16)    0.581
    Ventricular              95.4                   92.2                    0.36 (0.13--0.99)         0.049[^†^](#TN2){ref-type="table-fn"}     0.40 (0.14--1.20)    0.010[^†^](#TN2){ref-type="table-fn"}
    Other                    87.4                   87.4                    0.85 (0.33--2.16)         0.727                                     0.91 (0.30--2.83)    0.877
  Histology                                                                                                                                                          
    ET                       92.1                   88.2                    1 \[Reference\]                                                     1 \[Reference\]      
    OAT                      93.6                   93.6                    0.64 (0.25--1.65)         0.358                                     1.83 (0.20--17.33)   0.596
    DAOT                     59.1                   59.1                    5.65 (2.45--13.08)        \<0.001[^†^](#TN2){ref-type="table-fn"}   5.14 (1.72--15.39)   0.003[^†^](#TN2){ref-type="table-fn"}

*P \< 0.05, statistically significant*.

Kaplan--Meier curves were plotted to compare the CSS of LGBSG patients by different variates. The result showed that age group (*P* = 0.013), WHO grade (*P* = 0.018), surgery (*P* = 0.0012), and histology (*P* \< 0.0001) showed significant difference ([Figure 2](#F2){ref-type="fig"}). To assess the benefit of adjuvant therapy in the non-GTR group, one additional Kaplan--Meier curve was plotted. The result showed that patients who received RT or RT combined with CT had worse survival (*P* = 0.0077) ([Figure 3](#F3){ref-type="fig"}). The decision tree identified that histological-type DAOT (*P* \< 0.001) was the most distinguishable factor for survival period ([Figure 4](#F4){ref-type="fig"}).

![Kaplan--Meier curves for patients with LGBSG by different variates. **(A)** Age group, **(B)** sex, **(C)** race, **(D)** marital status, **(E)** WHO grade, **(F)** surgery, **(G)** tumor size, **(H)** metastasis, **(I)** adjuvant therapy, **(J)** tumor extension, **(K)** histology.](fonc-10-00391-g0002){#F2}

![Kaplan--Meier curve for patients with LGBSG in non-GTR group **(A)** and GTR group **(B)** treated with different adjuvant therapies. Kaplan--Meier curve for pediatric patients **(C)** and adult patients **(D)** with different histology types.](fonc-10-00391-g0003){#F3}

![Decision tree for the management of low-grade brainstem glioma patient.](fonc-10-00391-g0004){#F4}

Prognostic Nomogram for CSS and OS
----------------------------------

The population was randomly divided into training group (*n* = 152) and validation group (*n* = 153) ([Table 3](#T3){ref-type="table"}). We applied L1-penalized (Lasso) regression model to further identify prognostic factors for the CSS ([Figure 5](#F5){ref-type="fig"}) and OS ([Figure S1](#SM1){ref-type="supplementary-material"}) of LGBSG patients. Race, surgery, histology, and adjuvant therapy were incorporated into the nomogram for CSS ([Figure 6](#F6){ref-type="fig"}). And metastasis, age group, histology, adjuvant therapy, and WHO grade were incorporated into the nomogram for OS ([Figure S2](#SM1){ref-type="supplementary-material"}). The calibration curve for the probability of postoperative CSS ([Figure 6](#F6){ref-type="fig"}) and OS ([Figure S2](#SM1){ref-type="supplementary-material"}) at 5- and 8-year showed that there was a good consistency between the predicted survival probability and the actual survival probability in the data set. The C-index of internal validation for CSS and OS prediction was 0.87 (95% CI, 0.78--0.96) and 0.78 (95% CI, 0.70--0.86), respectively. The time-dependent ROC curve and area under curve (AUC) were established. Generally, the AUCs for CSS ([Figure 7](#F7){ref-type="fig"}) and OS ([Figure S3](#SM1){ref-type="supplementary-material"}) at different time points in training and validation cohort were \~0.7, which suggested the nomogram was accurate and effective at different time points. The clinical use was evaluated by DCA; the 5-year DCA curves in training and validation cohort for CSS nomogram ([Figure 8](#F8){ref-type="fig"}) and OS nomogram ([Figure S4](#SM1){ref-type="supplementary-material"}) yield larger net benefits than the model including surgery only.

###### 

Training and validation cohort for nomogram to predict 5- and 8-year cancer-specific survival rates of low-grade brainstem glioma patient.

                                  **Training *n* (%)**   **Validation *n* (%)**   ***P***
  ------------------------------- ---------------------- ------------------------ ---------
  Age                                                                             1.000
    ≥22 Adult                     70 (23.0)              70 (23.0)                
    \<22 Pediatric                82 (26.9)              83 (27.1)                
  Sex                                                                             0.448
    Female                        62 (20.3)              70 (23.0)                
    Male                          90 (29.5)              83 (27.2)                
  Race                                                                            0.199
    White                         126 (41.3)             135 (44.3)               
    Black                         14 (4.6)               13 (4.3)                 
    Asian or Pacific Islander     12 (3.9)               5 (1.6)                  
    Marital status                                                                0.417
    Unmarried                     108 (35.4)             116 (38.0)               
    Married                       44 (14.4)              37 (12.2)                
  WHO grade                                                                       0.272
    I                             63 (20.7)              74 (24.3)                
    II                            89 (29.2)              79 (25.8)                
  Surgery                                                                         0.399
    Local excision/biopsy         34 (11.2)              26 (8.5)                 
    STR                           29 (9.5)               36 (11.8)                
    GTR                           89 (29.2)              91 (29.8)                
  Size                                                                            0.862
    ≤ 3.6 cm                      80 (26.2)              78 (25.6)                
    \>3.6 cm                      72 (23.6)              75 (24.6)                
  Metastasis                                                                      0.287
    No                            150 (49.2)             147 (48.2)               
    Yes                           2 (0.6)                6 (2.0)                  
    Adjuvant therapy                                                              0.920
    No/unknown                    83 (27.2)              79 (25.9)                
    Both                          9 (3.0)                9 (3.0)                  
    Radiotherapy                  49 (16.0)              51 (16.7)                
    Chemotherapy                  11 (3.6)               14 (4.6)                 
  Extension                                                                       0.731
    Brainstem                     61 (22.0)              59 (19.3)                
    Cerebellum                    14 (4.6)               11 (3.6)                 
    Ventricular                   53 (17.4)              52 (17.0)                
    Other                         24 (7.9)               31 (10.2)                
    Cancer-specific death event                                                   1
    Alive                         138 (45.3)             138 (45.2)               
    Dead                          14 (4.6)               15 (4.9)                 
    Vital status                                                                  0.595
    Alive                         130 (42.6)             135 (44.3)               
    Dead                          22 (7.2)               18 (5.9)                 

![L1-penalized (Lasso) regression model were applied to further identified prognostic factors in training cohort. Race, surgery, histology, and adjuvant therapy were identified for CSS **(A)**. LASSO coefficient profiles of the features **(B)**. Ten-time cross-validation for tuning paremeter selection in the Lasso Model.](fonc-10-00391-g0005){#F5}

![Nomogram and internal calibration for cancer-specific survival rate. **(A)** Nomogram to predict 5- and 8-year CSS rates of low-grade brainstem glioma patients. The internal calibration curve to predict 5-year CSS rate in training cohort **(B)** and validation cohort **(C)**. The internal calibration curve to predict 8-year CSS rate in training cohort **(D)** and validation cohort **(E)**.](fonc-10-00391-g0006){#F6}

![Time-dependent ROC curve and areas under ROC curve at different time points. Areas under ROC curve of 5- and 8-year cancer-specific survival rates in training cohort **(A)** and validation cohort **(B)**. Areas under ROC curve at different time points in training cohort **(C)** and validation cohort **(D)**.](fonc-10-00391-g0007){#F7}

![Decision curve analysis for the nomogram and the model including surgery only in the prediction of the cancer-specific survival rates of patients at 5-year point in training cohort **(A,C)** and validation cohort **(B,D)**.](fonc-10-00391-g0008){#F8}

Discussion {#s4}
==========

Marked differences were observed in the epidemiological and biological characteristics of pediatric and adult patients with LGBSG. The multivariate analysis showed that the pediatric group was a significant and independent predictor of better OS and CSS. At the time of data collection, the CSS rates for pediatric and adult patients were 93.9 and 86.4% (*P* = 0.042), respectively. For pediatric patients with LGBSG, one retrospective study carried out at the Mayo clinic including 48 pediatric patients with LGBSG showed a median OS of 177.6 months and 5-year OS rate of 67% ([@B21]). Another retrospective study of 52 pediatric focal LGBSG patients reported a 5-year OS rate of 98% ([@B20]). For adult LGBSG patients, Reithmeier et al. ([@B6]) reported that the median OS for 30 WHO grade II BSG patients was 26.2 months, and Kesari et al. ([@B22]) reported that the median OS for 16 WHO grade I patients was 83 months. Generally, the results of other clinical studies support our conclusion that pediatric patients have a better survival than adult patients. In this present cohort, our analysis showed that more pediatric patients had tumors \>3.6 cm, and more adult patients had tumors involving the ventricular system, which had not been reported by other studies yet.

To investigate the effect of tumor characteristics on patient survival, we performed univariate and multivariate analyses and plotted Kaplan--Meier curves and decision tree. Our analysis revealed that WHO grade II was independently associated with worse CSS and OS in univariate analysis. The Kaplan--Meier curve also showed that the patients with WHO grade II tumor had worse survival rate. In this cohort, the 10-year CSS rates of patients with WHO grade I tumor and with WHO grade II tumor were 55.1 and 44.9%, respectively. Consistently, Ahmed et al. ([@B21]) reported that the 5-year OS rate of patients with WHO grade I tumors was significantly higher than that of patients with WHO grade II tumors in a study with 48 pediatric LGBSG patients (71 vs. 52%, *P* = 0.08). In clinical studies investigating adult BSG patients, those with WHO grade I tumors exhibited better survival rate than patients WHO grade II tumor ([@B6]). In addition, we divided the histological type into DAOT, OAT, and ET according to the 2016 WHO classification of tumors of central nerves system. And data analysis showed that DAOT was an important predictor for worse survival. The 10-year CSS rate of patients with DAOT and ET were 59.1 and 88.2%, respectively. This phenomenon had not been reported by other groups yet, which gave us a new insight about LGBSG.

Surgical treatment of the brainstem tumor has often been considered to be a difficult operation due to its critical position and crucial fundamental function. However, the advances in neuroimaging techniques (high-resolution MRI), anesthesia and neurosurgery have rendered resection of brainstem tumors feasible. Based on our analysis, GTR was significantly associated with better CSS and OS in univariate analysis when compared with patients treated with biopsy, but lost its significance in multivariate analysis. And this might be caused by the small sample size analyzed (*n* = 180) as we did not include the patients with unknown surgery status. The Kaplan--Meier curve confirmed that the patients receiving GTR had the highest survival rate (*P* = 0.0012). The 10-year CSS rates for patients treated with GTR and biopsy were 93.1 and 81.3%, respectively. So far, several studies have been reported concerning partial and even complete resection of brainstem tumor, and clinical outcomes in such studies are positive ([@B23]--[@B25]). A study conducted by Mayo Clinic on pediatric LGBSG patients concluded that tumor resection vs. biopsy only improved patient survival with statically increased 5-year OS rate (85 vs. 50%, *P* = 0.002) ([@B21]). Teo and Siu ([@B23]) reported a 100% 5-year OS rate of 23 pediatric LGBSG patients treated with endoscope-assisted microsurgery. Lundar et al. ([@B14]) performed resections on 15 pediatric patients diagnosed with low-grade midbrain glioma. They reported prolonged survival period of the patients. This study also found that tumor extension to ventricular system was a significant predictor of CSS by univariate and multivariate analyses. A population-based study focusing on HGBSG also concluded that ventricular system involvement may increase patient survival at 9 months compared with those with tumors confined to the brainstem ([@B9]). And this might be because tumors involving the ventricular system are more amenable to surgical resection. Although there is high heterogeneity that existed within different clinical studies, we could make a conclusion that most of the LGSBG patients benefited from GTR with prolonged survival. On the basis of the present analysis and results from other clinical studies ([Table 4](#T4){ref-type="table"}), it is considerable to suggest the safe maximal surgical resection as an effective treatment for LGBSG patients.

###### 

Studies reporting prognostic factors of pediatric low-grade brainstem glioma patients.

  **References**              **Patient included**        **Patient number**   **Median follow-up (mo)**   **Prognostic factors**
  --------------------------- --------------------------- -------------------- --------------------------- --------------------------------------
  Sandri et al. ([@B13])      Focal BSG                   17                   25                          GTR
  Fried et al. ([@B15])       LGBSG                       96                   57.6                        RT and CT was not associated with OS
  Klimo et al. ([@B20])       Focal LGBSG                 52                   120                         GTR, intrinsic tumor
  Ahmed et al. ([@B21])       LGBSG                       48                   177.6                       GTR, WHO grade, diffuse tumor
  Lundar et al. ([@B14])      Low-grade midbrain glioma   15                   96                          GTR
  Upadhyaya et al. ([@B12])   LGBSG                       23                   106                         Combination of surgery, RT and CT

Gross total resection plays an important role in the management of LGBSG patients and is considered to be a favorable predictor of better CSS and OS. However, for patients undergoing STR or biopsy only with residual lesion, there is no consensus as to whether they benefit from upfront postoperative adjuvant therapy (RT/CT). Generally, our results show that more adult LGBSG patients received RT, whereas more pediatric LGBSG patients were treated with CT for adjuvant therapy. This is because that RT has been reported to cause neurocognitive deficits and academic achievement problems in pediatric patients ([@B26]). Surprisingly, the univariate analysis results showed that RT was associated with worse CSS and OS, but this effect was lost after the correction of multivariate analysis. At the same time, Kaplan--Meier curve showed that adjuvant therapy added no benefits in patients with GTR and non-GTR. Ahmed et al. ([@B21]) also concluded that postoperative RT was associated with decreased OS based on univariate analysis. Given that RT was preferentially performed in adult patients or those who received no surgery and biopsy only was an important reason, this selection bias may account for this effect. Furthermore, univariate analysis showed that CT was not significantly associated with CSS and OS. Indeed, no CT regimen has been proven to be effective for LGBSG patients. Only few cases were reported to have a good response to CT ([@B14], [@B27], [@B28]). In addition, the Kaplan--Meier curves plotted both in all patients (*n* = 305) and non-GTR group (*n* = 125) supported that adjuvant therapy provided no clinical benefits. A clinical study including 96 pediatric patients with LGBSG reported that upfront adjuvant therapy (RT/CT) did not significantly improve the prognosis of patients with residual tumor compared with observation only ([@B15]). In summary, upfront adjuvant therapy is not beneficial to CSS and OS. Therefore, observation may be a safe alternative for LGBSG patients receiving STR or biopsy only with residual lesion.

This study has the following limitations. Although the SEER database contains a large number of records, it lacks other important information. For instance, data about the concrete position and growth pattern of tumor were not accessible in SEER database, which were important for tumor categorization and evaluating the prognosis of patients with LGBSG ([@B20], [@B21], [@B29]). Moreover, other clinical features of patients including functional status and neurologic symptoms were not available, which were reported to be predictive factors of patient prognosis ([@B30]--[@B32]). In addition, the surgical approach, radiation dosage, and CT protocol were not included in our analysis, although these factors influence the patient prognosis. And we do not know the detail information about how the tumor size was measured. Another weakness of this study is that there are 61 patients with specific histological diagnosis having the record of "no surgery" in the SEER database, which is confusing. So we did not include these 61 patients in the data set so as to make reliable conclusion. Given that the surgical experience is growing and efforts are made to attempt preferable adjuvant therapy methods ([@B16], [@B33]--[@B35]), the present study based on cases reported between 2004 and 2015 could not capture the most updated clinical evidence.

The strengths of this study include being the largest population-based real world study about LGBSG from SEER database. This study confirmed many findings in other single-center small dataset clinical studies with increased strength and low bias. This study describes, for the first time, the characteristics and prognostic factors of adult patients with LGBSG and compared the differences between pediatric and adult patients with LGBSG. Moreover, an accurate and effective nomogram was established to predict CSS and OS rate of LGBSG patients.

Conclusion {#s5}
==========

This population-based real world study of 165 pediatric and 140 adult LGBSG patients demonstrates that there are differences between these two groups. And safe maximal surgical resection was suggested as an effective treatment according to our data analysis and other clinical studies, yet with caution surgical resection may result in significant neurological deficits. Observation seems to be optional for patients with residual tumor after incomplete surgical resection because upfront adjuvant therapy had no effect on CSS according to the analysis. This study provides valuable data highlighting the need for prospective clinical studies in order to validate outcomes.
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